Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 9 of 151

  1. ADX-102 Ophthalmic Solution (0.5%)

    Aldeyra Therapeutics

    Dry Eye Syndromes

    phase 2 small molecule completed

    1 trial

  2. ADX-2191

    Aldeyra Therapeutics

    Retinitis Pigmentosa

    phase 2 small molecule completed

    1 trial

  3. ADX-629

    Aldeyra Therapeutics

    Nephrotic Syndrome

    phase 2 small molecule terminated

    1 trial

  4. ADX-629

    Aldeyra Therapeutics

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  5. ADX-629

    Aldeyra Therapeutics

    Alcohol Hepatitis

    phase 2 small molecule completed

    1 trial

  6. ADX-629

    Aldeyra Therapeutics

    Ethanol Intoxication

    phase 2 small molecule completed

    1 trial

  7. ADX-629

    Aldeyra Therapeutics

    Covid19

    phase 2 small molecule completed

    1 trial

  8. ADX-629

    Aldeyra Therapeutics

    Chronic Cough

    phase 2 small molecule completed

    1 trial

  9. ADX-629

    Aldeyra Therapeutics

    Atopic Asthma

    phase 2 small molecule completed

    1 trial

  10. ADX-629 (Open-label)

    Aldeyra Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  11. ADX-N05

    Jazz Pharmaceuticals Ireland Limited

    Narcolepsy

    phase 2 small molecule completed

    2 trials

  12. ADX10059

    Addex Therapeutics

    Gastroesophageal Reflux

    phase 2 small molecule completed

    2 trials

  13. ADX10059

    Addex Therapeutics

    Migraine

    phase 2 small molecule terminated

    1 trial

  14. ADX48621

    Addex Therapeutics

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  15. AECOPD

    Fondazione Telethon ETS

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule active

    1 trial

  16. AEF0117

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Abuse

    phase 2 small molecule completed

    1 trial

  17. AEVI-001

    Avalo Therapeutics

    Attention Deficit Hyperactivity Disorder

    phase 2 small molecule completed

    2 trials

  18. AFM13

    Artiva Biotherapeutics

    Relapsed or Refractory Hodgkin Lymphoma

    phase 2 small molecule terminated

    1 trial

  19. AG-013736

    Pfizer

    Thyroid Neoplasms

    phase 2 small molecule completed

    1 trial

  20. AG-120

    Agios Netherlands B.V.

    Chondrosarcoma

    phase 2 small molecule active

    1 trial

  21. AG-221-AML-005

    Celgene Europe Limited

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  22. AG-348

    Agios Netherlands B.V.

    Thalassemia

    phase 2 small molecule active

    1 trial

  23. AG10

    BridgeBio Oncology Therapeutics

    Familial ATTR-CM (ATTRm-CM, or FAC)

    phase 2 small molecule completed

    1 trial

  24. AG10

    BridgeBio Oncology Therapeutics

    Amyloid Cardiomyopathy

    phase 2 small molecule active

    1 trial

  25. AG946-C-003

    Lacuna Pharma Pty Ltd

    Sickle Cell Disease

    phase 2 small molecule active

    1 trial

  26. AGMB-129

    Agomab Therapeutics NV

    Fibrostenotic Crohn's Disease

    phase 2 small molecule active

    2 trials

  27. AGN 211745

    Allergan Pharmaceuticals International Limited

    Choroid Neovascularization

    phase 2 small molecule terminated

    1 trial

  28. AH0003

    Lacuna Pharma Pty Ltd

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  29. AIR DNase™

    Protalix BioTherapeutics

    Cystic Fibrosis

    phase 2 small molecule active

    1 trial

  30. AIRC Id. 21939

    Fondazione Telethon ETS

    Metastatic DTC

    phase 2 small molecule active

    1 trial

  31. AK0529

    Shanghai University of Traditional Chinese Medicine

    RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

    phase 2 small molecule completed

    1 trial

  32. AK104

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Resectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  33. AK104

    Akeso

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  34. AK105 and anlotinib

    The First People's Hospital of Lianyungang

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  35. AK112

    Summit Therapeutics

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  36. AK112-210

    Akeso

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  37. AK117

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  38. AKB-6548

    Akebia Europe Limited

    Anemia

    phase 2 small molecule completed

    4 trials

  39. AKCEA-ANGPTL3-LRX

    IONIS PHARMACEUTICALS INC

    Homozygous Familial Hypercholesterolemia

    phase 2 small molecule terminated

    1 trial

  40. AKCEA-ANGPTL3-LRx

    IONIS PHARMACEUTICALS INC

    Familial Chylomicronemia Syndrome

    phase 2 small molecule completed

    1 trial

  41. AKCEA-ANGPTL3-LRx

    IONIS PHARMACEUTICALS INC

    Familial Partial Lipodystrophy

    phase 2 small molecule completed

    1 trial

  42. AL-335

    Janssen Cilag International NV

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  43. AL8326

    Lacuna Pharma Pty Ltd

    Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage., Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage.

    phase 2 small molecule active

    1 trial

  44. AL8326

    Lacuna Pharma Pty Ltd

    - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment., - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment.

    phase 2 small molecule active

    1 trial

  45. ALD518

    CSL Behring GmbH

    Oral Mucositis

    phase 2 mab terminated

    1 trial

  46. ALDARA 5% cream, Keramod® gel

    Lacuna Pharma Pty Ltd

    Actinic keratosis

    phase 2 small molecule active

    1 trial

  47. ALDESLEUKIN , TIL cells

    Disc Medicine

    Ovarian carcinoma

    phase 2 small molecule active

    1 trial

  48. ALDESLEUKIN for Germ Cell Tumors refractory to salvage chemotherapy

    The George Institute

    Germ Cell Tumors refractory to salvage chemotherapy

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.